Sensei Bio reports Q4 2024 cash of $41.3M; Phase 1/2 solnerstotug data shows 14% ORR in PD-(L)1 resistant tumors

Sensei Biotherapeutics, Inc.

Preliminary Phase 1/2 dose expansion data: 14% ORR (3x historical PD-(L)1 rechallenge rates) and 62% DCR in PD-(L)1 resistant hot tumors; one complete response in Merkel cell carcinoma.
Target enrollment of 60 patients achieved in dose expansion cohort; full data expected by year-end 2025.
Net loss $30.2M for FY2024 (vs $34.1M FY2023); cash, equivalents and marketable securities $41.3M as of Dec 31, 2024, with runway into Q2 2026.
Solnerstotug well-tolerated: no dose-limiting toxicities; majority of adverse events Grade 1-2; 7% Grade 1 cytokine release syndrome.
Corporate updates: Q4 restructuring, appointment of Josiah Craver as Principal Financial Officer, and Dr. Ron Weitzman as part-time CMO.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-25-066261
form_type: 8-K
ticker: SNSE
cik: 0001829802
company_name: Sensei Biotherapeutics, Inc.
filed_at: 2025-03-28T23:59:59+00:00
discovered_at: 2026-05-14T18:03:05.135366+00:00
generated_at: 2026-05-24T03:15:44.371799+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: positive
materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-25-066261
json_url: https://secwatch.observer/filing/0001193125-25-066261.json
markdown_url: https://secwatch.observer/filing/0001193125-25-066261.md
text_url: https://secwatch.observer/filing/0001193125-25-066261.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1829802/000119312525066261/0001193125-25-066261-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1829802/000119312525066261/d927069d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-25-066261

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.